Ciprofloxacin-resistant salmonella Enterica serotype Typhi, United States, 1999-2008

Emerging Infectious Diseases

Volumn 17, Issue 6, 2011, Pages 1095-1098

  Medalla, Felicita ^a   Sjölund Karlsson, Maria ^a   Shin, Sanghyuk ^b   Harvey, Emily ^c   Joyce, Kevin ^a   Theobald, Lisa ^a   Nygren, Benjamin L ^a   Pecic, Gary ^a   Gay, Kathryn ^a   Austin, Jana ^a   Stuart, Andrew ^a   Blanton, Elizabeth ^a   Mintz, Eric D ^a   Whichard, Jean M ^a   Barzilay, Ezra J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CALIFORNIA EMERGING INFECTIONS PROGRAM   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOXITIN; CEFTIOFUR; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; KANAMYCIN; NALIDIXIC ACID; OFLOXACIN; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GYRA GENE; HUMAN; INDIA; MALE; NONHUMAN; PARC GENE; PRESCHOOL CHILD; PULSED FIELD GEL ELECTROPHORESIS; SALMONELLA TYPHI; SCHOOL CHILD; TRAVEL; TYPHOID FEVER; UNITED STATES;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; SALMONELLA TYPHI; TYPHOID FEVER; UNITED STATES; YOUNG ADULT;

EID: 79957644147     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1706.100594     Document Type: Article

References (15)

1. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. 1998;158:633-638. doi:10.1001/archinte.158.6.633
2. Connor BA, Schwartz E. Typhoid and paratyphoid fever in travelers. Lancet Infect Dis. 2005;5:623-628. doi:10.1016/S1473-3099(05)70239-5
3. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2006. MMWR. 2008;55:32,77.
4. Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA. 2000;283:2668-2673. doi:10.1001/jama.283.20.2668
5. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, et al. Typhoid fever in the United States, 1999-2006: trends in quinolone-resistant cases among international travelers. JAMA. 2009;302:859-865. doi:10.1001/jama.2009.1229
6. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet multicenter retrospective cohort study. Antimicrob Agents Chemother. 2008;52:1278-1284. doi:10.1128/AAC.01509-07
7. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): human isolates final report, 2008. Atlanta: US Department of Health and Human Services; 2010.
8. Cooke FJ, Wain J. The emergence of antibiotic resistance in typhoid fever. Travel Med Infect Dis. 2004;2:67-74. doi:10.1016/j.tmaid.2004.04.005
9. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug- resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007;51:819-825. doi:10.1128/AAC.00447-06
10. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents. 2005;25:358-373. doi:10.1016/j.ijantimicag.2005.02.006
11. Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P, et al. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India. J Antimicrob Chemother. 2006;58:1139-1144. doi:10.1093/jac/dkl391
12. Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. J Antimicrob Chemother. 2006;58:733-740. doi:10.1093/jac/dkl333
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Wayne (PA): The Institute; 2010.
14. Ribot EM, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for Pulse Net. Foodborne Pathog Dis. 2006;3:59-67. doi:10.1089/fpd.2006.3.59
15. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241-246. doi:10.1086/649541